Pharmaceutical brands need to do more to create and distribute “relevant and meaningful” content, according to a new report released last Thursday by Gartnerthat highlights the importance of improving digital strategies in the sector.
The first Gartner L2 Digital IQ Index: Pharmaceutical Rx U.S. study found that most brands in the pharmaceutical industry have not been able to pivot from a brand-centric approach to one that puts the patient at the heart of the experience and messages. Gartner noted that today’s consumers are both sceptical and savvy and that brands must, in turn, go to extra lengths to ensure that their needs are being met.
Gartner ranked 88 pharmaceutical brands in the US based on their performance in digital endeavours, and it did so by analysing more than a thousand data points across “critical dimensions”, such as social media, content marketing and site functionality. The primary takeaway is that while digital marketing efforts are meeting an adequate standard, much more can still be done.
Three-quarters of the brands were able to achieve a rank of “average” or better according to Gartner, which said the performance was impressive in part due to the “unprecedented” levels of regulation and scrutiny in the sector that can often hamper marketing campaigns.
The importance of serving up better content was highlighted by the fact that two-thirds of consumers say they use credible information that they have read or viewed to improve their own decision-making processes. Gartner said that many brand websites are still “content-poor” and that just half have up-to-date conversation guides or patient stories.
“It’s not enough to have average digital capabilities these days – pharmaceutical brands must ensure that their content is present, relevant and meaningful enough to take action on,” Gartner’s sector lead, Chris Beland, said.
He added: “Pharmaceutical brands in the U.S. face unprecedented levels of scrutiny and regulation, including strict limitations that have a profound impact on how they market to consumers. Despite these difficulties, consumers continue to look to brands’ digital channels for credible information and guidance.”
Paid search is also a key battleground for pharmaceuticals, as 68% say they regularly engage in competitive keyword bidding. Gartner noted that brands that focus their budgets on category search terms usually drive better return on investment but said these efforts must also be supported by more organic strategies.
This theory is strengthened by data in the study showing brands with effective social, mobile and email content efforts can deliver a larger portion of website traffic and general performance. Going mobile is crucial, as 83% of all traffic is now centred on mobile sites. Gartner also urged brands to incorporate prominent calls to action in content to generate better ROI.
Only three of the 88 brands analysed came away with a “genius”
rating. These were Repatha, FASENRA and Humira. A further 28 are classified as “gifted”,
while 37 are “average”. At the other end of the spectrum, 11 pharmaceutical
brands received a “feeble” ranking.